MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.72 and traded as high as $2.08. MediciNova shares last traded at $1.99, with a volume of 31,933 shares.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the stock. StockNews.com assumed coverage on shares of MediciNova in a report on Friday. They issued a "hold" rating on the stock. D. Boral Capital initiated coverage on shares of MediciNova in a report on Monday, December 2nd. They set a "buy" rating and a $9.00 price target on the stock.
View Our Latest Stock Report on MNOV
MediciNova Stock Down 1.5 %
The stock's fifty day moving average price is $2.03 and its 200 day moving average price is $1.73. The stock has a market cap of $96.13 million, a PE ratio of -9.33 and a beta of 0.84.
Institutional Investors Weigh In On MediciNova
An institutional investor recently raised its position in MediciNova stock. Geode Capital Management LLC grew its holdings in MediciNova, Inc. (NASDAQ:MNOV - Free Report) by 10.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 505,966 shares of the biopharmaceutical company's stock after acquiring an additional 47,201 shares during the period. Geode Capital Management LLC owned 1.03% of MediciNova worth $1,063,000 as of its most recent SEC filing. 9.90% of the stock is currently owned by institutional investors and hedge funds.
MediciNova Company Profile
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
See Also
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
